

가 Tor emi fene

Tamoxi fen

Comparison of Tamoxifen and Toremifene as Adjuvant Treatment in Node-negative Postmenopausal Breast Cancer

Sehwan Han, MD., Keun Ho Yang, MD., Byung Noe Bae, MD., Ki Hwan Kim, MD., Hong Joo Kim, MD., Young Duck Kim, MD. and Hong Yong Kim, MD.

Purpose: To evaluate the differences in therapeutic efficacy and toxicity profiles between adjuvant toremifene and tamoxifen in postmenopausal breast cancer patients.


Methods: Toremifene 40 mg (n=115) and tamoxifen 20 mg (n=116) were administered daily for more than 2 years after curative surgery for lymph node-negative breast cancer. Toxicity profiles were compared between the two groups and the patient survival rate was also analyzed.

Results: Sweating and hot flashes were the most common symptoms in the two groups (toremifene vs. tamoxifen=47.8% vs. 49.1%). Increase of vaginal discharge (39.1% vs. 36.2%) and weight gain (21.7% vs. 24.1%) were the next following adverse effects. There was no significant difference in adverse effect between the two groups. During the median follow-up period of 25 months (range: 9-38 months), five (4.3%) and four (3.3%) patients treated by toremifene and tamoxifen, respectively, had recurrent disease.

Conclusion: The clinical outcome and adverse effect profiles of toremifene were similar to those of tamoxifen. Toremifene at 40 mg/day seems to be as safe and effective as tamoxifen at 20 mg/day in the treatment of postmenopausal, node-negative, breast cancer. However, a longer follow-up study is needed to verify this. (J Korean Surg Soc 2002; 63:283-286)

Key Words: Breast cancer, Side effect, Tamoxifen, Toremifene, Treatment
: , , , Tamoxifen, Toremifen

Department of Surgery, Inje University Sanggye Paik Hospital, Seoul, Korea



: , 7 761-1
 © 139-707,
 Tel: 950-1018, Fax: 950-1955
 E-mail: shwhan@unitel.co.kr
 : 2002 7 22 , : 2002 8 14

toremifene 가 . . . 4 4
 toremifene 가 . . .
 toremifene 6
 toremifene 가 . . .
 toremifene 40 mg 115
 tamoxifen 20 mg 116
 toremifene
 가
 (ER)
 (PR) 2
 231 . toremifene 가
 115 , tamoxifen 가 116 .
 가 2 cm 가 132 (59.5%), 2 cm 가
 99 (40.5%) . (histologic grade)
 Bloom-Richardson 1 43
 , 2 110 , 3 78 .
 (modified radical mastectomy)
 가 148 , 가 83 .
 99 (Table 1).
 7 10 toremi-
 fene 40 mg tamoxifen 20 mg 1 .
 4 2
 가

Table 1. Clinical profiles of the patient

Characteristics	Toremifene (n=115)		Tamoxifen (n=116)	
	No.	%	No.	%
Tumor size				
< 2 cm	63	54.8	69	59.5
2 cm	52	45.2	47	40.5
Histologic grade				
I	23	20.1	20	17.2
II	54	46.8	56	48.3
III	38	33.1	40	34.5
Primary treatment				
Mastectomy	77	66.9	71	61.2
Segmental resection	38	33.1	45	38.8
Radiotherapy				
Yes	47	40.8	52	44.8
No	68	59.2	64	55.2

Toremifene 63 (54.8%)
 가 2 cm tamoxifen
 가 2 cm 69 (59.5%) .
 toremifene
 23 (20.1%), tamoxifen 20
 (17.2%) . toremife 38 (33.1%)
 tamoxifen 40 (34.5%) . toremi-
 fene 77 (66.9%)가 tamoxifen
 71 (61.2%) .
 toremifene 33.1%, tamoxifen 38.8%
 (40.8%), tamoxifen 52 (44.8%) .
 , ,
 2
 4 4
 . 가 가
 (49.1%) (43.9%) .
 가(36.2%) 가(24.1%)가
 3 7
 가
 (Table 2). toremifene 2 (1.6%),
 tamoxifen 3 (2.5%)
 . Toremifene
 1 14

Table 2. Frequency of adverse effects

Effect	Toremifene (n=115)		Tamoxifen (n=116)	
	No.	%	No.	%
Sweating	55	47.8	57	49.1
Hot flashes	49	42.6	51	43.9
Vaginal discharge	45	39.1	42	36.2
Vaginal bleeding	9	7.8	9	7.7
Nausea	11	9.6	10	8.6
Rash	2	1.6	3	2.5
Weight gain	25	21.7	28	24.1

Table 3. Change of endometrial thickness after toremifene and tamoxifen treatment

	Mean endometrial thickness						Range
	6	12	18	24	30	36 (month)	
Toremifene	3.1	3.2	3.6	3.6	3.6	3.8	2.3 22 mm
Tamoxifen	3.0	3.2	3.6	3.7	3.7	3.8	2.4 23 mm

Table 4. Clinical outcome

Event	Toremifene (n=115)		Tamoxifen (n=116)	
	No.	%	No.	%
Recurrence				
Locoregional	3	2.6	3	2.5
Systemic	2	1.7	1	0.8

Median f/u = 25 months (range: 9 38 months)

toremifene tamoxifen 가
(Table 3). 가 4 mm 가

. Toremifene 23 (20%)
가 4 mm
9 (7.8%)

. Tamoxifen 26 (22.4%)
12 (10.3%)

25 (: 9 38) toremifene
3 (2.6%), tamoxifen 3

. Toremifene 3
2 tamoxifen 3

. Toremifene
1 가

2 (1.7%), tamoxifen 1 (0.8%)
가
(Table 4).

가 가
가 5 가
가 가
toremifene 가
toremifene tamoxifen
(5,6)
가 가
가 가
tamoxifen 5
2
가 tamoxifen (7,8)
tamoxifen
tamoxifen
(9-12) Toremifene 가
tamoxifen
6 가가
toremifene tamoxifen
가 (13)
tamoxifen 가
1.0 7.5 가
(14-16) toremifene
(13) toremifene
5 toremifene
. Toremifene
가
toremifene
toremifene 40 mg 60 mg
가 가



가
Breast Cancer Study Group (IBCSG) International
fene 40 mg 60 mg toremi-
IBCSG 가 toremifene
.
toremifene 40 mg
tamoxifen 20 mg
.
toremifene
tamoxifen
가 5 10 toremifene
.

REFERENCES

- 1) Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: Twenty-eight years later. *J Clin Oncol* 1995;13:513-29.
- 2) Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. *Lancet* 1998;351:1451-67.
- 3) Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *J Natl Cancer Inst* 1998;90:1371-8.
- 4) Pyrhonen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen S, et al. Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: A randomized double-blind The Nordic phase III study. *Br J Cancer* 1997;76:270-7.
- 5) Homesley HD, Shemano I, Gams R, Harry DS, Hickox PG, Rebar RW, et al. Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women. *Am J Clin Oncol* 1993;16:117-22.
- 6) Di Salle E, Zaccheo T, Ornati G. Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. *J Steroid Biochem* 1990;36:203-6.
- 7) Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. *Lancet* 1998;351:1451-67.
- 8) Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. *J Natl Cancer Inst* 1996;88:1543-9.
- 9) Love RR. Prospects for antiestrogen chemoprevention of breast cancer. *J Natl Cancer Inst* 1990;82:18-22.
- 10) Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. *N Engl J Med* 1992;326:852-6.
- 11) Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. *Ann Intern Med* 1991;115:860-4.
- 12) Turken S, Siris E, Seldin D, Flaster E, Heyman G, Lindsay R. Effects of tamoxifen on spinal bone density in women with breast cancer. *J Natl Cancer Inst* 1989;1086-88.
- 13) Holli K, Valavaara R, Blanco G, Kataja V, Hietanen P, Flander M, et al. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. *J Clin Oncol* 2000;18:3487-94.
- 14) Fisher B, Constantino JP, Redmond CK, Fisher ER, Wickerham DC, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. *J Natl Cancer Inst* 1994;86:527-37.
- 15) van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeny LA, Gibrere CH, Otter R, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. *Lancet* 1994;343:448-52.
- 16) Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early-stage breast cancer and second primary malignancies: Stockholm Breast Cancer Study Group. *J Natl Cancer Inst* 1995;87:645-51.
- 17) Ellmen J, Werner D, Hakulinen P, Keiling R, Forgeot P, Falkson G, et al. Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients. *Cancer Chemother Pharmacol* 2000;402-8.